Mimma Rizzo

18PUBLICATIONS
80CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Artificial life and complex adaptive systemsMolecular targetsTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Jul 29, 2026
Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study).

|Jan 23, 2026
Identification of Predictive Genomic Biomarkers in Metastatic Clear Cell Renal Cell Carcinoma: A Comprehensive Analysis of Real-World Clinicogenomic Data.

Mimma Rizzo, Gaetano Pezzicoli, Camilla Porta

|Jan 07, 2026
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study.

Thomas Büttner, Mimma Rizzo, Laura Bernal Vaca

|Dec 11, 2025
Obtaining Patient-Reported Outcome Data via a Home Patient Monitoring App: Development, Implementation, and Validation of Novel Interface Terminology.

Lucia Sacchi, Giordano Lanzola, Silvana Quaglini

|Jul 08, 2025
Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 Study.

Mimma Rizzo, Andrey Soares, Shilpa Gupta

|Jul 03, 2025
HER2-Positive Urothelial Carcinoma: Current Evidence on Targeted Agents and Immunotherapy-Based Combinations.

Federica Ciciriello, Gaetano Pezzicoli, Antonello Biasi

Pageof 3

Frequent Collaborators

5 joint publications

Camillo Porta

3 joint publications

Alexandra Kogan

3 joint publications

Savannah Lucia Catherina Glaser

3 joint publications

David Glasspool